<p>在週四發佈的一份研究報告中，瑞銀集團的股票分析師將 Teva Pharmaceutical Industries（紐約證券交易所代碼：TEVA - 獲取免費報告）的目標股價從 36.00 美元上調至 42.00 美元，Benzinga 報道。該券商目前對該股票給予 “買入” 評級。瑞銀集團的目標股價暗示該公司股價有 19.89% 的上漲潛力。</p>
<ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
<p>其他幾位研究分析師也最近對該股票發表了評論。Weiss Ratings 在 4 月 20 日的報告中重申了對 Teva Pharmaceutical Industries 股票的 “賣出（d-）” 評級。Jefferies Financial Group 在 1 月 6 日的報告中將 Teva Pharmaceutical Industries 的目標股價從 29.00 美元上調至 40.00 美元，並給予該股票 “買入” 評級。高盛集團在 2 月 9 日的報告中將 Teva Pharmaceutical Industries 的目標股價從 36.00 美元上調至 45.00 美元，並給予該股票 “買入” 評級。美國銀行在 4 月 9 日的報告中將 Teva Pharmaceutical Industries 的目標股價從 38.00 美元上調至 42.00 美元，並給予該股票 “買入” 評級。最後，Scotiabank 在 1 月 29 日的報告中將 Teva Pharmaceutical Industries 的目標股價從 35.00 美元上調至 40.00 美元，並給予該股票 “行業表現優於大盤” 評級。九位投資分析師對該股票給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標股價為 41.00 美元。</p>
<p><strong>獲取我們對 TEVA 的最新分析</strong></p>
<h2>Teva Pharmaceutical Industries 股票下跌 1.0%</h2>
<ul>
<li>Teva Pharma：為什麼這家仿製藥巨頭現在是一個明智的買入選擇</li>
</ul>
<p>週四，紐約證券交易所 TEVA 的股價下跌 0.35 美元，跌至 35.03 美元。該股票交易了 16,081,784 股，而其平均交易量為 8,323,869 股。該公司的速動比率為 0.80，流動比率為 1.04，債務與股本比率為 1.89。Teva Pharmaceutical Industries 的 52 周低點為 14.99 美元，52 周高點為 37.35 美元。該公司的市值為 402.8 億美元，市盈率為 29.19，市盈增長比率為 2.75，貝塔值為 0.76。該公司的 50 日移動平均價格為 31.14 美元，200 日移動平均價格為 29.29 美元。</p>
<p>Teva Pharmaceutical Industries（紐約證券交易所代碼：TEVA - 獲取免費報告）最後一次發佈季度財報是在 3 月 31 日，報告顯示該季度每股收益為 0.53 美元。Teva Pharmaceutical Industries 的淨利潤率為 8.16%，股本回報率為 46.28%。該季度的收入為 39.8 億美元。賣方分析師預計 Teva Pharmaceutical Industries 在當前財政年度將發佈 2.6 美元的每股收益。</p>
<h2>內部人士下注</h2>
<ul>
<li>2 只准備在 2025 年飆升的仿製藥股票</li>
</ul>
<p>在其他新聞中，內部人士 Mark Sabag 在 3 月 17 日的交易中出售了 62,102 股公司的股票。該股票以平均價格 30.14 美元出售，總價值為 1,871,754.28 美元。交易完成後，內部人士持有 224,940 股公司股票，價值約為 6,779,691.60 美元。這代表其持股比例下降了 21.64%。該銷售在向 SEC 提交的文件中披露，文件可通過此鏈接訪問。此外，首席執行官 Richard D. Francis 在 3 月 3 日的交易中出售了 442,935 股公司的股票。該股票以平均價格 32.36 美元出售，總交易額為 14,333,376.60 美元。交易完成後，首席執行官持有 642,099 股公司的股票，價值約為 20,778,323.64 美元。該交易使其持股比例下降了 40.82%。該銷售的披露信息可在 SEC 文件中找到。在過去 90 天內，內部人士已出售 920,901 股公司股票，價值 30,056,789 美元。當前公司內部人士持有 0.54% 的股票。</p>
<h2>Teva Pharmaceutical Industries 的機構交易</h2>
<p>一些大型投資者最近買入和賣出了該公司的股票。Global Retirement Partners LLC 在第四季度將其在 Teva Pharmaceutical Industries 的股份增加了 27.3%。Global Retirement Partners LLC 目前擁有 1,360 股公司股票，價值 42,000 美元，此前在該期間內購買了 292 股。Captrust Financial Advisors 在第四季度將其在 Teva Pharmaceutical Industries 的股份增加了 2.1%。Captrust Financial Advisors 目前擁有 14,715 股公司股票，價值 459,000 美元，此前在該期間內購買了 302 股。Banque Cantonale Vaudoise 在第四季度將其在 Teva Pharmaceutical Industries 的股份增加了 6.3%。Banque Cantonale Vaudoise 目前擁有 5,133 股公司股票，價值 160,000 美元，此前在該期間內購買了 306 股。Ethic Inc.在第四季度將其在 Teva Pharmaceutical Industries 的股份增加了 1.8%。Ethic Inc.目前擁有 18,127 股公司股票，價值 566,000 美元，此前在該期間內購買了 325 股。最後，Allworth Financial LP 在第四季度將其在 Teva Pharmaceutical Industries 的股份增加了 53.8%。Allworth Financial LP 目前擁有 941 股公司股票，價值 29,000 美元，此前在該期間內購買了 329 股。機構投資者和對沖基金持有該公司 54.05% 的股票。</p>
<h2>更多 Teva Pharmaceutical Industries 新聞</h2>
<p>以下是本週影響 Teva Pharmaceutical Industries 的主要新聞故事：</p>
<ul>
<li>積極情緒：第一季度業績超出預期——Teva 報告第一季度收入約為 39.8 億美元，每股收益為 0.53 美元（超出預期），主要受 Austedo、Ajovy 和 Uzedy 等品牌藥物增長的推動，這支撐了最近的反彈。TEVA 第一季度收益超出預期</li>
<li>積極情緒：收購擴大增長管道——Teva 同意收購 Emalex Biosciences（交易金額約為 9 億美元），該公司開發的 ecopipam 是一種即將提交新藥申請的晚期 Tourette 綜合症治療藥物，補充了 Teva 的神經科學業務，並支持短期和長期增長。Teva 收購 Emalex Biosciences</li>
<li>積極情緒：分析師提高目標價——Truist 將其目標價提高至 45 美元（買入），Piper Sandler 重申超配並將目標價上調至 42 美元，顯示出分析師的持續信心，併為股票提供了上行支持。Truist 目標價上調 Piper Sandler 重申</li>
<li>積極情緒：機構興趣和融資活動——報道指出，黑石集團的融資/興趣顯著，且期權活動（大量看漲期權購買）上升，表明買方對股價上漲的信心。黑石融資分析</li>
<li>中性情緒：指引更新但符合預期——Teva 重申 2026 財年每股收益指引（大約在 2.57 至 2.77 之間），與市場共識大致一致，留有執行空間以推動進一步上漲。第一季度業績及指引</li>
<li>中性情緒：期權流動——報告顯示異常大量的看漲期權購買，這可能會放大日內波動，但並不改變公司前景的基本面。</li>
<li>消極情緒：仿製藥面臨逆風——管理層指出仿製藥表現疲軟（包括 lenalidomide 仿製藥收入下降），這是一個反覆出現的壓力點，抑制了盈利超預期的表現，意味着需要持續執行以維持增長。路透社：品牌藥物推動業績</li>
<li>消極情緒：短期獲利回吐風險——在經歷了多日約 10-12% 的上漲後，部分回調是正常的，因為交易者鎖定收益；這種動態可能在短期內超過新的積極消息。</li>
</ul>
<h2>關於 Teva 製藥工業</h2>
<p>(獲取免費報告)</p>
<p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA 是一家以色列跨國製藥公司，也是全球最大的仿製藥製造商之一。公司的核心業務包括仿製藥的開發、生產和營銷，以及一系列專科品牌藥物的組合。Teva 向全球市場提供成品劑型和活性藥物成分（API），並在多個國家運營製造和研究設施。</p>
<p>Teva 的產品範圍涵蓋口服固體劑型、注射劑、吸入產品及其他劑型，涉及中樞神經系統疾病、呼吸系統、腫瘤、疼痛和傳染病等治療領域。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票超過 Teva 製藥工業</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Teva 製藥工業嗎？</h2>
<p>在考慮 Teva 製藥工業之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Teva 製藥工業並不在名單上。</p>
<p>雖然 Teva 製藥工業目前在分析師中獲得中性買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>查看這五隻股票</p>

梯瓦制藥

美國制藥 ETF - iShares

<p>瑞士銀行集團已將梯瓦製藥（NYSE:TEVA）的目標價格從 36.00 美元上調至 42.00 美元，維持 “買入” 評級。這意味着相較於前一交易日的收盤價，潛在上漲幅度為 19.89%。其他分析師也給予了積極評級，普遍評級為 “適度買入”，平均目標價格為 41.00 美元。梯瓦的股票最近交易價格為 35.03 美元，下跌 1.0%。該公司在上個季度報告的收入為 39.8 億美元，每股收益為 0.53 美元</p>

<p>Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its price target hoisted by stock analysts at UBS Group from $36.00 to $42.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a &#34;buy&#34; rating on the stock. UBS Group's target price suggests a potential upside of 19.89% from the company's previous close.</p>
<div class="lb-trans"><p>在週四發佈的一份研究報告中，瑞銀集團的股票分析師將 Teva Pharmaceutical Industries（紐約證券交易所代碼：TEVA - 獲取免費報告）的目標股價從 36.00 美元上調至 42.00 美元，Benzinga 報道。該券商目前對該股票給予 “買入” 評級。瑞銀集團的目標股價暗示該公司股價有 19.89% 的上漲潛力。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
</div><p>Several other research analysts have also recently commented on the stock. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, January 6th. The Goldman Sachs Group boosted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, February 9th. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, April 9th. Finally, Scotiabank boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a &#34;sector outperform&#34; rating in a report on Thursday, January 29th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $41.00.</p>
<div class="lb-trans"><p>其他幾位研究分析師也最近對該股票發表了評論。Weiss Ratings 在 4 月 20 日的報告中重申了對 Teva Pharmaceutical Industries 股票的 “賣出（d-）” 評級。Jefferies Financial Group 在 1 月 6 日的報告中將 Teva Pharmaceutical Industries 的目標股價從 29.00 美元上調至 40.00 美元，並給予該股票 “買入” 評級。高盛集團在 2 月 9 日的報告中將 Teva Pharmaceutical Industries 的目標股價從 36.00 美元上調至 45.00 美元，並給予該股票 “買入” 評級。美國銀行在 4 月 9 日的報告中將 Teva Pharmaceutical Industries 的目標股價從 38.00 美元上調至 42.00 美元，並給予該股票 “買入” 評級。最後，Scotiabank 在 1 月 29 日的報告中將 Teva Pharmaceutical Industries 的目標股價從 35.00 美元上調至 40.00 美元，並給予該股票 “行業表現優於大盤” 評級。九位投資分析師對該股票給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標股價為 41.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on TEVA</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 TEVA 的最新分析</strong></p>
</div><h2>Teva Pharmaceutical Industries Stock Down 1.0%</h2>
<div class="lb-trans"><h2>Teva Pharmaceutical Industries 股票下跌 1.0%</h2>
</div><ul>
<li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma：為什麼這家仿製藥巨頭現在是一個明智的買入選擇</li>
</ul>
</div><p>NYSE TEVA traded down $0.35 on Thursday, hitting $35.03. 16,081,784 shares of the stock were exchanged, compared to its average volume of 8,323,869. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The company has a market cap of $40.28 billion, a PE ratio of 29.19, a PEG ratio of 2.75 and a beta of 0.76. The company has a 50-day moving average price of $31.14 and a 200-day moving average price of $29.29.</p>
<div class="lb-trans"><p>週四，紐約證券交易所 TEVA 的股價下跌 0.35 美元，跌至 35.03 美元。該股票交易了 16,081,784 股，而其平均交易量為 8,323,869 股。該公司的速動比率為 0.80，流動比率為 1.04，債務與股本比率為 1.89。Teva Pharmaceutical Industries 的 52 周低點為 14.99 美元，52 周高點為 37.35 美元。該公司的市值為 402.8 億美元，市盈率為 29.19，市盈增長比率為 2.75，貝塔值為 0.76。該公司的 50 日移動平均價格為 31.14 美元，200 日移動平均價格為 29.29 美元。</p>
</div><p>Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $3.98 billion during the quarter. Sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries（紐約證券交易所代碼：TEVA - 獲取免費報告）最後一次發佈季度財報是在 3 月 31 日，報告顯示該季度每股收益為 0.53 美元。Teva Pharmaceutical Industries 的淨利潤率為 8.16%，股本回報率為 46.28%。該季度的收入為 39.8 億美元。賣方分析師預計 Teva Pharmaceutical Industries 在當前財政年度將發佈 2.6 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只准備在 2025 年飆升的仿製藥股票</li>
</ul>
</div><p>In other news, insider Mark Sabag sold 62,102 shares of the company's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total value of $1,871,754.28. Following the completion of the transaction, the insider owned 224,940 shares in the company, valued at approximately $6,779,691.60. This represents a 21.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Richard D. Francis sold 442,935 shares of the company's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the completion of the transaction, the chief executive officer owned 642,099 shares of the company's stock, valued at approximately $20,778,323.64. The trade was a 40.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 920,901 shares of company stock worth $30,056,789. 0.54% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Mark Sabag 在 3 月 17 日的交易中出售了 62,102 股公司的股票。該股票以平均價格 30.14 美元出售，總價值為 1,871,754.28 美元。交易完成後，內部人士持有 224,940 股公司股票，價值約為 6,779,691.60 美元。這代表其持股比例下降了 21.64%。該銷售在向 SEC 提交的文件中披露，文件可通過此鏈接訪問。此外，首席執行官 Richard D. Francis 在 3 月 3 日的交易中出售了 442,935 股公司的股票。該股票以平均價格 32.36 美元出售，總交易額為 14,333,376.60 美元。交易完成後，首席執行官持有 642,099 股公司的股票，價值約為 20,778,323.64 美元。該交易使其持股比例下降了 40.82%。該銷售的披露信息可在 SEC 文件中找到。在過去 90 天內，內部人士已出售 920,901 股公司股票，價值 30,056,789 美元。當前公司內部人士持有 0.54% 的股票。</p>
</div><h2>Institutional Trading of Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>Teva Pharmaceutical Industries 的機構交易</h2>
</div><p>A number of large investors have recently bought and sold shares of the business. Global Retirement Partners LLC boosted its stake in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company's stock worth $42,000 after purchasing an additional 292 shares during the period. Captrust Financial Advisors boosted its stake in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Captrust Financial Advisors now owns 14,715 shares of the company's stock worth $459,000 after purchasing an additional 302 shares during the period. Banque Cantonale Vaudoise boosted its stake in Teva Pharmaceutical Industries by 6.3% during the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company's stock worth $160,000 after purchasing an additional 306 shares during the period. Ethic Inc. boosted its stake in Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Ethic Inc. now owns 18,127 shares of the company's stock worth $566,000 after purchasing an additional 325 shares during the period. Finally, Allworth Financial LP boosted its stake in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company's stock worth $29,000 after purchasing an additional 329 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近買入和賣出了該公司的股票。Global Retirement Partners LLC 在第四季度將其在 Teva Pharmaceutical Industries 的股份增加了 27.3%。Global Retirement Partners LLC 目前擁有 1,360 股公司股票，價值 42,000 美元，此前在該期間內購買了 292 股。Captrust Financial Advisors 在第四季度將其在 Teva Pharmaceutical Industries 的股份增加了 2.1%。Captrust Financial Advisors 目前擁有 14,715 股公司股票，價值 459,000 美元，此前在該期間內購買了 302 股。Banque Cantonale Vaudoise 在第四季度將其在 Teva Pharmaceutical Industries 的股份增加了 6.3%。Banque Cantonale Vaudoise 目前擁有 5,133 股公司股票，價值 160,000 美元，此前在該期間內購買了 306 股。Ethic Inc.在第四季度將其在 Teva Pharmaceutical Industries 的股份增加了 1.8%。Ethic Inc.目前擁有 18,127 股公司股票，價值 566,000 美元，此前在該期間內購買了 325 股。最後，Allworth Financial LP 在第四季度將其在 Teva Pharmaceutical Industries 的股份增加了 53.8%。Allworth Financial LP 目前擁有 941 股公司股票，價值 29,000 美元，此前在該期間內購買了 329 股。機構投資者和對沖基金持有該公司 54.05% 的股票。</p>
</div><h2>More Teva Pharmaceutical Industries News</h2>
<div class="lb-trans"><h2>更多 Teva Pharmaceutical Industries 新聞</h2>
</div><p>Here are the key news stories impacting Teva Pharmaceutical Industries this week:</p>
<div class="lb-trans"><p>以下是本週影響 Teva Pharmaceutical Industries 的主要新聞故事：</p>
</div><ul>
<li>Positive Sentiment: Q1 results beat expectations — Teva reported Q1 revenue of ~$3.98B and EPS of $0.53 (beat), driven by growth in branded drugs including Austedo, Ajovy and Uzedy, which underpinned the recent rally. TEVA Q1 Earnings Top Estimates</li>
<li>Positive Sentiment: Acquisition expands growth pipeline — Teva agreed to acquire Emalex Biosciences (deal reported up to ~$900M) for ecopipam, a late‑stage, NDA‑ready Tourette therapy that complements Teva’s neuroscience franchise and supports near‑ and long‑term growth. Teva to Acquire Emalex Biosciences</li>
<li>Positive Sentiment: Analysts raising targets — Truist raised its price target to $45 (buy) and Piper Sandler reaffirmed overweight and lifted its target to $42, signaling continued analyst confidence and providing upside support for the stock. Truist price target raisePiper Sandler reaffirmation</li>
<li>Positive Sentiment: Institutional interest and financing activity — Coverage pieces flagged a meaningful financing/interest from Blackstone and elevated options activity (large call buying), suggesting buy‑side conviction behind the move higher. Blackstone financing analysis</li>
<li>Neutral Sentiment: Guidance updated but in line — Teva reiterated FY‑2026 EPS guidance (roughly 2.57–2.77), broadly consistent with consensus, leaving room for execution to drive further upside. Q1 results &amp; guidance</li>
<li>Neutral Sentiment: Options flow — Unusually large call buying was reported, which can amplify intraday moves but is not a fundamental change to the company’s outlook.</li>
<li>Negative Sentiment: Generics headwinds remain — Management flagged weaker generics performance (including lower lenalidomide generic revenue), a recurring pressure point that tempers the earnings beat and means continued execution is needed to sustain growth. Reuters: branded drugs drive results</li>
<li>Negative Sentiment: Short‑term profit‑taking risk — After a multi‑day ~10–12% run, some pullback is normal as traders book gains; that dynamic can outweigh fresh positive headlines in the near term.</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：第一季度業績超出預期——Teva 報告第一季度收入約為 39.8 億美元，每股收益為 0.53 美元（超出預期），主要受 Austedo、Ajovy 和 Uzedy 等品牌藥物增長的推動，這支撐了最近的反彈。TEVA 第一季度收益超出預期</li>
<li>積極情緒：收購擴大增長管道——Teva 同意收購 Emalex Biosciences（交易金額約為 9 億美元），該公司開發的 ecopipam 是一種即將提交新藥申請的晚期 Tourette 綜合症治療藥物，補充了 Teva 的神經科學業務，並支持短期和長期增長。Teva 收購 Emalex Biosciences</li>
<li>積極情緒：分析師提高目標價——Truist 將其目標價提高至 45 美元（買入），Piper Sandler 重申超配並將目標價上調至 42 美元，顯示出分析師的持續信心，併為股票提供了上行支持。Truist 目標價上調 Piper Sandler 重申</li>
<li>積極情緒：機構興趣和融資活動——報道指出，黑石集團的融資/興趣顯著，且期權活動（大量看漲期權購買）上升，表明買方對股價上漲的信心。黑石融資分析</li>
<li>中性情緒：指引更新但符合預期——Teva 重申 2026 財年每股收益指引（大約在 2.57 至 2.77 之間），與市場共識大致一致，留有執行空間以推動進一步上漲。第一季度業績及指引</li>
<li>中性情緒：期權流動——報告顯示異常大量的看漲期權購買，這可能會放大日內波動，但並不改變公司前景的基本面。</li>
<li>消極情緒：仿製藥面臨逆風——管理層指出仿製藥表現疲軟（包括 lenalidomide 仿製藥收入下降），這是一個反覆出現的壓力點，抑制了盈利超預期的表現，意味着需要持續執行以維持增長。路透社：品牌藥物推動業績</li>
<li>消極情緒：短期獲利回吐風險——在經歷了多日約 10-12% 的上漲後，部分回調是正常的，因為交易者鎖定收益；這種動態可能在短期內超過新的積極消息。</li>
</ul>
</div><h2>About Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>關於 Teva 製藥工業</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries Ltd. NYSE: TEVA 是一家以色列跨國製藥公司，也是全球最大的仿製藥製造商之一。公司的核心業務包括仿製藥的開發、生產和營銷，以及一系列專科品牌藥物的組合。Teva 向全球市場提供成品劑型和活性藥物成分（API），並在多個國家運營製造和研究設施。</p>
</div><p>Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.</p>
<div class="lb-trans"><p>Teva 的產品範圍涵蓋口服固體劑型、注射劑、吸入產品及其他劑型，涉及中樞神經系統疾病、呼吸系統、腫瘤、疼痛和傳染病等治療領域。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Teva Pharmaceutical Industries</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Teva 製藥工業</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=TEVA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Teva 製藥工業嗎？</h2>
</div><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Teva 製藥工業之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Teva 製藥工業並不在名單上。</p>
</div><p>While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Teva 製藥工業目前在分析師中獲得中性買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

UBS Group Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Market Beat

瑞銀集團

Jefferies Financial

高盛

美國銀行

Bank of Nova Scottia

GS Hldg R

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

瑞銀集團對梯瓦製藥（NYSE:TEVA）的股票價格發佈了樂觀的預測